Mometasonfuroat Glenmark (Mometasone Furoate)

Mometasone furoate binds to intracellular glucocorticoid receptors, forming a complex that enters the cell nucleus and alters gene transcription. This up‑regulates anti‑inflammatory proteins while down‑regulating pro‑inflammatory cytokines, leading to decreased leukocyte infiltration and reduced skin inflammation.

The dosage and frequency are determined by the prescribing healthcare professional based on the severity of the condition, the area of skin being treated and patient age. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for topical mometasone furoate in pregnancy or lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency class I/II corticosteroid, offering strong anti‑inflammatory effects with a relatively low risk of systemic absorption when used appropriately. Compared with lower‑potency agents such as hydrocortisone, it provides faster symptom control but requires careful monitoring for skin‑related side effects.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures. Keep the container tightly closed when not in use to maintain product stability.

Apply a thin layer of the cream or ointment to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until it disappears, and wash hands before and after application unless the hands are the treatment site.

Serious risks include skin atrophy or thinning, development of telangiectasia, and secondary infections due to local immunosuppression. Prolonged or extensive use can also lead to systemic cortisol suppression, which may affect the hypothalamic‑pituitary‑adrenal axis.

Patients with known hypersensitivity to mometasone furoate or any formulation component should not use the product. It is also contraindicated on infected skin unless combined with appropriate antimicrobial therapy, and should be avoided in infants under two months unless specifically prescribed.